Etanercept biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical)

依那西普生物类似药（上海复旦张江生物医药）

Report date: 2022/05/26 17:06:25

Base Information

Drug NameEtanercept biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical)

Drug Alias NameRecombinant human TNF receptor p75-Fc fusion protein依那西普生物仿制药（上海复旦张江生物医药）重组人肿瘤坏死因子受体突变体-Fc融合蛋白(复旦张江)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors

TargetsTumor necrosis factor βTumor necrosis factor α

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusNDA/BLA

Highest Status in ChinaNDA/BLA

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsArthritis, Rheumatoid

Inactive IndicationsN/A

ATC CodeL04AB01